- Home
- HRTX vs RCS Comparison
HRTX vs RCS Comparison
Compare HRTX & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- RCS
- Stock Information
- Founded
- HRTX 1983
- RCS 1994
- Country
- HRTX United States
- RCS United States
- Employees
- HRTX N/A
- RCS N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- HRTX Health Care
- RCS Finance
- Exchange
- HRTX Nasdaq
- RCS Nasdaq
- Market Cap
- HRTX 276.1M
- RCS 329.4M
- IPO Year
- HRTX 1987
- RCS N/A
- Fundamental
- Price
- HRTX $1.33
- RCS $7.13
- Analyst Decision
- HRTX Strong Buy
- RCS
- Analyst Count
- HRTX 2
- RCS 0
- Target Price
- HRTX $4.50
- RCS N/A
- AVG Volume (30 Days)
- HRTX 2.2M
- RCS 141.1K
- Earning Date
- HRTX 08-08-2025
- RCS 01-01-0001
- Dividend Yield
- HRTX N/A
- RCS 10.12%
- EPS Growth
- HRTX N/A
- RCS N/A
- EPS
- HRTX N/A
- RCS N/A
- Revenue
- HRTX $149,694,000.00
- RCS N/A
- Revenue This Year
- HRTX $12.08
- RCS N/A
- Revenue Next Year
- HRTX $12.57
- RCS N/A
- P/E Ratio
- HRTX N/A
- RCS N/A
- Revenue Growth
- HRTX 9.78
- RCS N/A
- 52 Week Low
- HRTX $1.04
- RCS $4.51
- 52 Week High
- HRTX $2.68
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- HRTX 28.25
- RCS 57.05
- Support Level
- HRTX $1.31
- RCS $7.05
- Resistance Level
- HRTX $1.47
- RCS $7.22
- Average True Range (ATR)
- HRTX 0.11
- RCS 0.07
- MACD
- HRTX -0.04
- RCS -0.01
- Stochastic Oscillator
- HRTX 19.72
- RCS 48.89
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.